Tag: bite

Delta-Like Ligand 3 Targeted Therapies Market Overview

The market for delta-like ligand 3 (DLL3) targeted therapies is rapidly expanding due to the rising prevalence of small cell lung cancer (SCLC) and neuroendocrine tumors. Advancements in antibody-drug conjugate (ADC) technology and increased clinical trial activity are driving the development of DLL3-targeted therapies. Strategic collaborations and growing interest from biopharma companies are accelerating market […]